AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 14.535 USD -0.1%
Market Cap: 442.3m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

Operating Margin
AnaptysBio Inc

-257.8%
Current
-777%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-257.8%
=
Operating Profit
-147.4m
/
Revenue
57.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
AnaptysBio Inc
NASDAQ:ANAB
426.3m USD
-258%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
28%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country US
Market Cap 426.3m USD
Operating Margin
-258%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 311.8B USD
Operating Margin
28%
Country US
Market Cap 140.7B USD
Operating Margin
19%
Country US
Market Cap 115.7B USD
Operating Margin
38%
Country US
Market Cap 102.7B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
442.3m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
16.381 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-257.8%
=
Operating Profit
-147.4m
/
Revenue
57.2m
What is the Operating Margin of AnaptysBio Inc?

Based on AnaptysBio Inc's most recent financial statements, the company has Operating Margin of -257.8%.